

DRUGDEX®



As part of the Micromedex Healthcare Series, **DRUGDEX** from the Healthcare business of Thomson Reuters:

- Delivers complete information at the point of care—where decisions matter most.
- Is ideal for those who prescribe, order, dispense, or administer medications.
- Provides strength-of-evidence, recommendation, and efficacy ratings for all therapeutic uses.
- Is recognized by the centers for Medicare and Medicaid (CMS) as a reference standard for Medicare Part B and D and for Medicaid.

With quick access to relevant and timely drug facts, clinicians can decrease the risk of adverse drug events and save valuable time. Having a powerful resource like DRUGDEX at the point of care means clinicians get the facts they need to make critical decisions on FDA-approved and investigational prescription and nonprescription drugs as well as on non-U.S. preparations.

DRUGDEX is the ultimate drug resource with fully referenced, unbiased content covering dosage, pharmacokinetics, cautions, interactions, comparative efficacy, labeled and off-label indications, and clinical applications. DRUGDEX also spans international, FDA-approved, and nonprescription preparations.

Available formats include:

- Internet
- Intranet
- Mobile

FEATURES

- Comprehensive monographs for ease of reference.
- Unbiased, evidence-based information on 2,300+ drugs.
- Includes FDA-approved, non-U.S., OTC, and investigational drugs.
- Searchable by generic name, brand name, adverse effect, or indication.
- Includes a handheld component as well as dosing tools and calculators.

BENEFITS

- Reduces adverse drug events at the point of need.
- Enables a side-by-side comparison of drug tables.
- Offers the ability to compare off-label indications.

ABOUT THOMSON REUTERS

The Healthcare business of Thomson Reuters produces insights, information, benchmarks and analysis that enable organizations to manage costs, improve performance, and enhance the quality of healthcare. Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minn., Thomson Reuters employs more than 50,000 people in 93 countries. Thomson Reuters shares are listed on the New York Stock Exchange (NYSE: TRI); Toronto Stock Exchange (TSX: TRI); London Stock Exchange (LSE: TRIL); and Nasdaq (NASDAQ: TRIN).

thomsonreuters.com

Thomson Reuters
777 E. Eisenhower Parkway
Ann Arbor, MI 48108 USA
Phone +1 800 366 7526

©2008 Thomson Reuters.
All rights reserved. All brand names are trademarks or registered trademarks of their respective company
PRO-4689 09/08 MC

The screenshot displays the DRUGDEX web interface for ANIDULAFUNGIN. The left sidebar contains a table of contents with expandable sections: Overview, Dosing Information, Pharmacokinetics, Cautions, Clinical Applications, and References. The main content area shows the '0.0 Overview' section, which lists the drug's class (Antifungal), mechanism of action (Echinocandin, Glucan Synthetase Inhibitor), and dosing information for adult patients. The '1.0 Dosing Information' section is partially visible at the bottom.

Using a persistent document outline, clinicians can pinpoint critical drug facts with a minimal number of clicks.

